Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2017

View Archived Issues

Shire reports key events of second quarter 2017

Daiichi Sankyo signs investment contract with Osaka University spin-off Cuorips

Novel LpxC inhibitor demonstrates efficacy in mouse model of bubonic plague

Kiromic conducts four phase I/II trials of its TAPA-pulsed dendritic cell vaccine

Extracellular phosphorylation of EphB2 regulates pathological pain

First-in-human results for prophylactic mRNA-based rabies vaccine

Induced pluripotent stem cells used to generate neurons for study of tau aggregation

Cyclacel selects recommended phase II dose for CYC-065

Zynerba Pharmaceuticals presents topline data from phase II STAR 1 trial of ZYN-002

Alligator Bioscience and Stanford University expand immuno-oncology collaboration

Phase III OPTIMA trial of ThermoDox in primary liver cancer recommended to continue

Positive topline data from first patient cohort of PIONEER-HCM phase II trial of mavacamten

FDA issues complete response letter for latanoprostene bunod NDA

FibroGen reports phase II topline data on pamrevlumab in IPF

FDA awards orphan drug designation to Mytesi for short bowel syndrome

Gemphire presents topline data from ROYAL-1 phase IIb study of gemcabene

Zelboraf granted priority review and breakthrough therapy designation for Erdheim-Chester disease

Piclidenoson completes cardiodynamic safety study

Rebiotix initiates phase III trial of RBX-2660 to prevent recurrent C. difficile infection

Janssen reports results of APPROACH study of Ad26.Mos.HIV HIV-1 vaccine regimens

AntriaBio acquires rights to ActiveSite's plasma kallikrein inhibitor program

FDA grants orphan drug designation to tesevatinib for EGFR-mutated NSCLC

Mylan receives PEPFAR tentative approval for TLD fixed-dose combination regimen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...